| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 46.25% | 1.23% | 26.49% | 21.38% | 21.54% | 32.61% | 33.18% | 27.41% | 36.55% |
| Operating Margin | -116.95% | -337.87% | -595.98% | -473.70% | -428.79% | -453.39% | -255.44% | -170.12% | -244.28% |
| EBITDA Margin | -83.53% | -292.31% | -558.03% | -439.09% | -410.16% | -435.99% | -244.31% | -159.11% | -228.46% |
| Net Margin | -92.59% | -363.98% | -643.74% | -476.93% | -402.84% | -483.43% | -294.34% | -154.13% | -245.82% |
| Current Ratio | 1.98 | 1.06 | 1.40 | 4.38 | 12.47 | 5.23 | 1.07 | 5.09 | 0.43 |
| Quick Ratio | 1.64 | 0.70 | 1.12 | 3.55 | 11.91 | 4.86 | 0.94 | 4.85 | 0.33 |
| Debt / Equity | — | — | — | — | 0.00 | 0.47 | 5.56 | 0.89 | -0.13 |
| ROE | -59.42% | -316.66% | -241.78% | -53.17% | -21.49% | -117.17% | -825.05% | -182.46% | 46.52% |
| ROA | -35.87% | -146.10% | -108.44% | -43.12% | -19.21% | -68.00% | -98.70% | -74.57% | -230.31% |
| Asset Turnover | 0.39 | 0.40 | 0.17 | 0.09 | 0.05 | 0.14 | 0.34 | 0.48 | 0.94 |
| Book Value / Share | 8.16 | 27.83 | 2.82 | 0.86 | 1.22 | 0.34 | 0.24 | 1.43 | -18.60 |
Bionano Genomics develops genome analysis software that enables genomics laboratories to analyze and interpret genomic data across multiple platforms, generating comprehensive insights for research and clinical applications. The company's solutions are designed to detect genomic variations and provide a unified view of genome data, addressing critical questions in cancer diagnosis, genetic disease detection, and treatment planning. Bionano Genomics serves the genomics and clinical laboratory markets, offering tools that integrate data from various sequencing and analysis technologies. The company operates in the life sciences and healthcare technology sector, where it plays a role in advancing precision medicine and improving diagnostic capabilities for healthcare providers and research institutions worldwide.